276 related articles for article (PubMed ID: 34165261)
1. Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer.
Cao J; Li J; Yang X; Li P; Yao Z; Han D; Ying L; Wang L; Tian J
Cancer Med; 2021 Aug; 10(15):5375-5391. PubMed ID: 34165261
[TBL] [Abstract][Full Text] [Related]
2. Significance of KDM6A mutation in bladder cancer immune escape.
Chen X; Lin X; Pang G; Deng J; Xie Q; Zhang Z
BMC Cancer; 2021 May; 21(1):635. PubMed ID: 34051747
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K
J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658
[TBL] [Abstract][Full Text] [Related]
4. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
5. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
6. Identification of an immunotherapy-responsive molecular subtype of bladder cancer.
Song BN; Kim SK; Mun JY; Choi YD; Leem SH; Chu IS
EBioMedicine; 2019 Dec; 50():238-245. PubMed ID: 31735557
[TBL] [Abstract][Full Text] [Related]
7. A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer.
Fu Y; Sun S; Bi J; Kong C; Yin L
BMC Cancer; 2021 Jul; 21(1):810. PubMed ID: 34266411
[TBL] [Abstract][Full Text] [Related]
8. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
9. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
Front Immunol; 2020; 11():590618. PubMed ID: 33391264
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy.
Zhang YY; Li XW; Li XD; Zhou TT; Chen C; Liu JW; Wang L; Jiang X; Wang L; Liu M; Zhao YG; Li SD
Front Immunol; 2022; 13():1055304. PubMed ID: 36505486
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and
Li Y; Dong W; Zhang P; Zhang T; Ma L; Qu M; Ma X; Zhou X; He Q
Front Cell Dev Biol; 2021; 9():750897. PubMed ID: 34733851
[No Abstract] [Full Text] [Related]
13. Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.
Xie X; Dou CX; Luo MR; Zhang K; Liu Y; Zhou JW; Huang ZP; Xue KY; Liang HY; Ouyang AR; Ma SX; Yang JK; Zhou QZ; Guo WB; Liu CD; Zhao SC; Chen MK
Front Immunol; 2022; 13():946209. PubMed ID: 36569837
[TBL] [Abstract][Full Text] [Related]
14. Exploration of the prognostic effect of costimulatory genes in bladder cancer.
Su H; Liu Z; Zhang C; Deng Z; Su X; Wang Y; Liu W
J Gene Med; 2024 Jan; 26(1):e3655. PubMed ID: 38282148
[TBL] [Abstract][Full Text] [Related]
15. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
Front Immunol; 2020; 11():576603. PubMed ID: 33329543
[TBL] [Abstract][Full Text] [Related]
16. Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
Zhang S; Lv M; Cheng Y; Wang S; Li C; Qu X
BMC Cancer; 2021 Dec; 21(1):1324. PubMed ID: 34893046
[TBL] [Abstract][Full Text] [Related]
17. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
Zhang X; Zhang Y; Zhao L; Wang J; Li J; Wang X; Zhang M; Hu X
Front Immunol; 2022; 13():1014638. PubMed ID: 36569935
[TBL] [Abstract][Full Text] [Related]
18. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
[TBL] [Abstract][Full Text] [Related]
19. High expression of COL6A1 predicts poor prognosis and response to immunotherapy in bladder cancer.
Zhang X; Liu J; Yang X; Jiao W; Shen C; Zhao X; Wang Y
Cell Cycle; 2023 Mar; 22(5):610-618. PubMed ID: 36474424
[TBL] [Abstract][Full Text] [Related]
20. A novel risk score based on a combined signature of 10 immune system genes to predict bladder cancer prognosis.
Tang Y; Hu Y; Wang J; Zeng Z
Int Immunopharmacol; 2020 Oct; 87():106851. PubMed ID: 32763782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
